Natalizumab (Tysabri) for the treatment of anti-Hu associated paraneoplastic neurological syndromes

Trial Profile

Natalizumab (Tysabri) for the treatment of anti-Hu associated paraneoplastic neurological syndromes

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Neurological disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2016 Eudra reports recruiting with start date (03-02-2016), but NTR reports status as not yet recruiting with start date (15-02-2016), retained NTR since it is location specific.
    • 08 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top